{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:05:03Z","timestamp":1789704303536,"version":"4.0.1"},"reference-count":168,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T00:00:00Z","timestamp":1686700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004775","name":"Natural Science Foundation of Gansu Province","doi-asserted-by":"publisher","award":["21JR11RA075"],"award-info":[{"award-number":["21JR11RA075"]}],"id":[{"id":"10.13039\/501100004775","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004775","name":"Natural Science Foundation of Gansu Province","doi-asserted-by":"publisher","award":["GSHZTS 2022-04"],"award-info":[{"award-number":["GSHZTS 2022-04"]}],"id":[{"id":"10.13039\/501100004775","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Gansu Association for Science and Technology","award":["21JR11RA075"],"award-info":[{"award-number":["21JR11RA075"]}]},{"name":"Gansu Association for Science and Technology","award":["GSHZTS 2022-04"],"award-info":[{"award-number":["GSHZTS 2022-04"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Around 11% of all known gene lesions causing human genetic diseases are nonsense mutations that introduce a premature stop codon (PTC) into the protein-coding gene sequence. Drug-induced PTC readthrough is a promising therapeutic strategy for treating hereditary diseases caused by nonsense mutations. To date, it has been found that more than 50 small-molecular compounds can promote PTC readthrough, known as translational readthrough-inducing drugs (TRIDs), and can be divided into two major categories: aminoglycosides and non-aminoglycosides. This review summarizes the pharmacodynamics and clinical application potential of the main TRIDs discovered so far, especially some newly discovered TRIDs in the past decade. The discovery of these TRIDs brings hope for treating nonsense mutations in various genetic diseases. Further research is still needed to deeply understand the mechanism of eukaryotic cell termination and drug-induced PTC readthrough so that patients can achieve the greatest benefit from the various TRID treatments.<\/jats:p>","DOI":"10.3390\/biom13060988","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T03:18:46Z","timestamp":1686799126000},"page":"988","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Pharmaceuticals Promoting Premature Termination Codon Readthrough: Progress in Development"],"prefix":"10.3390","volume":"13","author":[{"given":"Shan","family":"Li","sequence":"first","affiliation":[{"name":"School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[{"name":"Central Laboratory, The First Hospital of Lanzhou University, Lanzhou 730000, China"},{"name":"Gansu Key Laboratory of Genetic Study of Hematopathy, The First Hospital of Lanzhou University, Lanzhou 730000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Shi","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyan","family":"Nie","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shasha","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengdie","family":"Ma","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Hu","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Chen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Applied Organic Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou 730000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiqiang","family":"Li","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4895-0924","authenticated-orcid":false,"given":"Xiaodong","family":"Xie","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/humu.20763","article-title":"A Meta-Analysis of Nonsense Mutations Causing Human Genetic Disease","volume":"29","author":"Mort","year":"2008","journal-title":"Hum. Mutat."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7203","DOI":"10.1038\/s41467-021-27423-0","article-title":"Cellular Variability of Nonsense-Mediated MRNA Decay","volume":"12","author":"Sato","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/brv.12657","article-title":"Deciphering the Molecular Mechanism of Stop Codon Readthrough","volume":"96","author":"Palma","year":"2021","journal-title":"Biol. Rev. Camb. Philos. Soc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1007\/s00018-021-03809-7","article-title":"Nonsense Suppression Therapies in Human Genetic Diseases","volume":"78","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Floquet, C., Hatin, I., Rousset, J.-P., and Bidou, L. (2012). Statistical Analysis of Readthrough Levels for Nonsense Mutations in Mammalian Cells Reveals a Major Determinant of Response to Gentamicin. PLoS Genet., 8.","DOI":"10.1371\/journal.pgen.1002608"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s10020-018-0024-7","article-title":"Advances in Therapeutic Use of a Drug-Stimulated Translational Readthrough of Premature Termination Codons","volume":"24","author":"Dabrowski","year":"2018","journal-title":"Mol. Med."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Lombardi, S., Testa, M.F., Pinotti, M., and Branchini, A. (2020). Molecular Insights into Determinants of Translational Readthrough and Implications for Nonsense Suppression Approaches. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21249449"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.neubiorev.2013.10.016","article-title":"Nonsense-Mediated MRNA Decay: Inter-Individual Variability and Human Disease","volume":"46","author":"Nguyen","year":"2014","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.pharmthera.2012.07.007","article-title":"Pharmaceutical Therapies to Recode Nonsense Mutations in Inherited Diseases","volume":"136","author":"Lee","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s40259-016-0157-6","article-title":"Targeting Nonsense Mutations in Diseases with Translational Read-Through-Inducing Drugs (TRIDs)","volume":"30","author":"Penner","year":"2016","journal-title":"BioDrugs"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/emmm.201201438","article-title":"A Comparative Evaluation of NB30, NB54 and PTC124 in Translational Read-through Efficacy for Treatment of an USH1C Nonsense Mutation","volume":"4","author":"Goldmann","year":"2012","journal-title":"EMBO Mol. Med."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Morais, P., Adachi, H., and Yu, Y.-T. (2020). Suppression of Nonsense Mutations by New Emerging Technologies. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21124394"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"6265","DOI":"10.1093\/nar\/13.17.6265","article-title":"Suppression of a Nonsense Mutation in Mammalian Cells in Vivo by the Aminoglycoside Antibiotics G-418 and Paromomycin","volume":"13","author":"Burke","year":"1985","journal-title":"Nucleic. Acids Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1146\/annurev-genom-091212-153527","article-title":"Therapeutics Based on Stop Codon Readthrough","volume":"15","author":"Keeling","year":"2014","journal-title":"Annu. Rev. Genom. Hum. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1006\/jmbi.2000.4420","article-title":"Structural Origins of Aminoglycoside Specificity for Prokaryotic Ribosomes","volume":"306","author":"Lynch","year":"2001","journal-title":"J. Mol. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.molmed.2012.09.008","article-title":"Sense from Nonsense: Therapies for Premature Stop Codon Diseases","volume":"18","author":"Bidou","year":"2012","journal-title":"Trends Mol. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Schilff, M., Sargsyan, Y., Hofhuis, J., and Thoms, S. (2021). Stop Codon Context-Specific Induction of Translational Readthrough. Biomolecules, 11.","DOI":"10.3390\/biom11071006"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"101546","DOI":"10.1016\/j.jbc.2021.101546","article-title":"Nonselective TRPC Channel Inhibition and Suppression of Aminoglycoside-Induced Premature Termination Codon Readthrough by the Small Molecule AC1903","volume":"298","author":"Bauer","year":"2022","journal-title":"J. Biol. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"E10899","DOI":"10.1073\/pnas.1715501114","article-title":"Aminoglycoside Interactions and Impacts on the Eukaryotic Ribosome","volume":"114","author":"Prokhorova","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"a027029","DOI":"10.1101\/cshperspect.a027029","article-title":"Aminoglycosides: An Overview","volume":"6","author":"Krause","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00467-018-4094-0","article-title":"The Aminoglycoside Geneticin Permits Translational Readthrough of the CTNS W138X Nonsense Mutation in Fibroblasts from Patients with Nephropathic Cystinosis","volume":"34","author":"Brasell","year":"2019","journal-title":"Pediatr. Nephrol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e52611","DOI":"10.7554\/eLife.52611","article-title":"Stop Codon Context Influences Genome-Wide Stimulation of Termination Codon Readthrough by Aminoglycosides","volume":"9","author":"Wangen","year":"2020","journal-title":"Elife"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Friesen, W.J., Johnson, B., Sierra, J., Zhuo, J., Vazirani, P., Xue, X., Tomizawa, Y., Baiazitov, R., Morrill, C., and Ren, H. (2018). The Minor Gentamicin Complex Component, X2, Is a Potent Premature Stop Codon Readthrough Molecule with Therapeutic Potential. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0206158"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1021\/acsmedchemlett.8b00472","article-title":"New in Vitro Assay Measuring Direct Interaction of Nonsense Suppressors with the Eukaryotic Protein Synthesis Machinery","volume":"9","author":"Ng","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1001\/jamadermatol.2021.5992","article-title":"Molecular and Clinical Outcomes After Intravenous Gentamicin Treatment for Patients With Junctional Epidermolysis Bullosa Caused by Nonsense Variants","volume":"158","author":"Mosallaei","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1001\/jamadermatol.2022.0112","article-title":"Evaluation of Systemic Gentamicin as Translational Readthrough Therapy for a Patient with Epidermolysis Bullosa Simplex with Muscular Dystrophy Owing to PLEC1 Pathogenic Nonsense Variants","volume":"158","author":"Maseda","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00109-002-0363-1","article-title":"Aminoglycoside Suppression of a Premature Stop Mutation in a Cftr\u2212\/\u2212 Mouse Carrying a Human CFTR-G542X Transgene","volume":"80","author":"Du","year":"2002","journal-title":"J. Mol. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1056\/NEJMoa022170","article-title":"Gentamicin-Induced Correction of CFTR Function in Patients with Cystic Fibrosis and CFTR Stop Mutations","volume":"349","author":"Wilschanski","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Sermet-Gaudelus, I., Renouil, M., Fajac, A., Bidou, L., Parbaille, B., Pierrot, S., Davy, N., Bismuth, E., Reinert, P., and Lenoir, G. (2007). In Vitro Prediction of Stop-Codon Suppression by Intravenous Gentamicin in Patients with Cystic Fibrosis: A Pilot Study. BMC Med., 5.","DOI":"10.1186\/1741-7015-5-5"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1172\/JCI7866","article-title":"Aminoglycoside Antibiotics Restore Dystrophin Function to Skeletal Muscles of Mdx Mice","volume":"104","author":"Cordier","year":"1999","journal-title":"J. Clin. Investig."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/ana.1023","article-title":"Gentamicin Treatment of Duchenne and Becker Muscular Dystrophy Due to Nonsense Mutations","volume":"49","author":"Wagner","year":"2001","journal-title":"Ann. Neurol."},{"key":"ref_32","first-page":"15","article-title":"Gentamicin Administration in Duchenne Patients with Premature Stop Codon. Preliminary Results","volume":"22","author":"Politano","year":"2003","journal-title":"Acta Myol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ana.22024","article-title":"Gentamicin-Induced Readthrough of Stop Codons in Duchenne Muscular Dystrophy","volume":"67","author":"Malik","year":"2010","journal-title":"Ann. Neurol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1182\/blood-2005-03-1307","article-title":"Aminoglycoside Suppression of Nonsense Mutations in Severe Hemophilia","volume":"106","author":"James","year":"2005","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/jb\/mvp185","article-title":"Transdermal Delivery of a Readthrough-Inducing Drug: A New Approach of Gentamicin Administration for the Treatment of Nonsense Mutation-Mediated Disorders","volume":"147","author":"Shiozuka","year":"2010","journal-title":"J. Biochem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s12519-021-00469-2","article-title":"Application of Topical Gentamicin\u2014A New Era in the Treatment of Genodermatosis","volume":"17","author":"Wang","year":"2021","journal-title":"World J. Pediatr."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.jid.2017.10.014","article-title":"Gentamicin-Induced Readthrough and Nonsense-Mediated MRNA Decay of SERPINB7 Nonsense Mutant Transcripts","volume":"138","author":"Ohguchi","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"adv00392","DOI":"10.2340\/00015555-3760","article-title":"Effect of Gentamicin Ointment in Patients with Nagashima-Type Palmoplantar Keratosis: A Double-Blind Vehicle-Controlled Study","volume":"101","author":"Li","year":"2021","journal-title":"Acta Derm. Venereol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1172\/JCI92707","article-title":"Gentamicin Induces Functional Type VII Collagen in Recessive Dystrophic Epidermolysis Bullosa Patients","volume":"127","author":"Woodley","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.ymthe.2020.03.006","article-title":"Gentamicin Induces Laminin 332 and Improves Wound Healing in Junctional Epidermolysis Bullosa Patients with Nonsense Mutations","volume":"28","author":"Kwong","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1111\/1346-8138.15230","article-title":"Gentamicin Induces COL17A1 Nonsense Mutation Readthrough in Junctional Epidermolysis Bullosa","volume":"47","author":"Li","year":"2020","journal-title":"J. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/ceo.13912","article-title":"Topical Gentamicin Ointment Induces LAMB3 Nonsense Mutation Readthrough and Improves Corneal Erosions in a Patient with Junctional Epidermolysis Bullosa","volume":"49","author":"Hung","year":"2021","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/sj.jid.5700031","article-title":"Aminoglycosides as Potential Pharmacogenetic Agents in the Treatment of Hailey\u2013Hailey Disease","volume":"126","author":"Kellermayer","year":"2006","journal-title":"J. Investig. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bjd.18718","article-title":"Treatment of Hereditary Hypotrichosis Simplex of the Scalp with Topical Gentamicin","volume":"183","author":"Peled","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1159\/000499906","article-title":"Attenuation of Severe Generalized Junctional Epidermolysis Bullosa by Systemic Treatment with Gentamicin","volume":"235","author":"Hammersen","year":"2019","journal-title":"Dermatology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"6583","DOI":"10.1093\/nar\/gkw638","article-title":"Novel Small Molecules Potentiate Premature Termination Codon Readthrough by Aminoglycosides","volume":"44","author":"Balgi","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1021\/acsmedchemlett.8b00610","article-title":"2-Aminothiazole-4-Carboxamides Enhance Readthrough of Premature Termination Codons by Aminoglycosides","volume":"10","author":"Rabea","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Ferguson, M.W., Gerak, C.A.N., Chow, C.C.T., Rastelli, E.J., Elmore, K.E., Stahl, F., Hosseini-Farahabadi, S., Baradaran-Heravi, A., Coltart, D.M., and Roberge, M. (2019). The Antimalarial Drug Mefloquine Enhances TP53 Premature Termination Codon Readthrough by Aminoglycoside G418. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0216423"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Hosseini-Farahabadi, S., Baradaran-Heravi, A., Zimmerman, C., Choi, K., Flibotte, S., and Roberge, M. (2021). Small Molecule Y-320 Stimulates Ribosome Biogenesis, Protein Synthesis, and Aminoglycoside-Induced Premature Termination Codon Readthrough. PLoS Biol., 19.","DOI":"10.1371\/journal.pbio.3001221"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1074\/jbc.M113.533588","article-title":"Designer Aminoglycosides That Selectively Inhibit Cytoplasmic Rather than Mitochondrial Ribosomes Show Decreased Ototoxicity","volume":"289","author":"Shulman","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1021\/jm801640k","article-title":"Development of Novel Aminoglycoside (NB54) with Reduced Toxicity and Enhanced Suppression of Disease-Causing Premature Stop Mutations","volume":"52","author":"Nudelman","year":"2009","journal-title":"J. Med. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00439-007-0410-7","article-title":"In Vitro and Ex Vivo Suppression by Aminoglycosides of PCDH15 Nonsense Mutations Underlying Type 1 Usher Syndrome","volume":"122","author":"Nudelman","year":"2007","journal-title":"Hum. Genet."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s00109-011-0787-6","article-title":"Suppression of CFTR Premature Termination Codons and Rescue of CFTR Protein and Function by the Synthetic Aminoglycoside NB54","volume":"89","author":"Rowe","year":"2011","journal-title":"J. Mol. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00109-010-0704-4","article-title":"Readthrough of Nonsense Mutations in Rett Syndrome: Evaluation of Novel Aminoglycosides and Generation of a New Mouse Model","volume":"89","author":"Brendel","year":"2011","journal-title":"J. Mol. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ymgme.2011.10.005","article-title":"The Designer Aminoglycoside NB84 Significantly Reduces Glycosaminoglycan Accumulation Associated with MPS I-H in the Idua-W392X Mouse","volume":"105","author":"Wang","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1016\/j.bmc.2010.03.060","article-title":"Repairing Faulty Genes by Aminoglycosides: Development of New Derivatives of Geneticin (G418) with Enhanced Suppression of Diseases-Causing Nonsense Mutations","volume":"18","author":"Nudelman","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ymgme.2013.12.007","article-title":"Long-Term Nonsense Suppression Therapy Moderates MPS I-H Disease Progression","volume":"111","author":"Gunn","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1021\/ol0269042","article-title":"Pyranmycins, a Novel Class of Aminoglycosides with Improved Acid Stability: The SAR of D-Pyranoses on Ring III of Pyranmycin","volume":"4","author":"Chang","year":"2002","journal-title":"Org. Lett."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00439-006-0245-7","article-title":"Novel Aminoglycosides Increase SMN Levels in Spinal Muscular Atrophy Fibroblasts","volume":"120","author":"Mattis","year":"2006","journal-title":"Hum. Genet."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1093\/hmg\/ddp333","article-title":"Delivery of a Read-through Inducing Compound, TC007, Lessens the Severity of a Spinal Muscular Atrophy Animal Model","volume":"18","author":"Mattis","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Mattis, V.B., Fosso, M.Y., Chang, C.-W., and Lorson, C.L. (2009). Subcutaneous Administration of TC007 Reduces Disease Severity in an Animal Model of SMA. BMC Neurosci., 10.","DOI":"10.1186\/1471-2202-10-142"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1080\/13543784.2020.1828862","article-title":"ELX-02: An Investigational Read-through Agent for the Treatment of Nonsense Mutation-Related Genetic Disease","volume":"29","author":"Kerem","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1080\/15476286.2017.1285480","article-title":"Characterization of New-Generation Aminoglycoside Promoting Premature Termination Codon Readthrough in Cancer Cells","volume":"14","author":"Bidou","year":"2017","journal-title":"RNA Biol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jcf.2021.01.009","article-title":"Targeting G542X CFTR Nonsense Alleles with ELX-02 Restores CFTR Function in Human-Derived Intestinal Organoids","volume":"20","author":"Crawford","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jcf.2021.09.020","article-title":"Functional Restoration of CFTR Nonsense Mutations in Intestinal Organoids","volume":"21","author":"Spelier","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Brasell, E.J., Chu, L.L., Akpa, M.M., Eshkar-Oren, I., Alroy, I., Corsini, R., Gilfix, B.M., Yamanaka, Y., Huertas, P., and Goodyer, P. (2019). The Novel Aminoglycoside, ELX-02, Permits CTNSW138X Translational Read-through and Restores Lysosomal Cystine Efflux in Cystinosis. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0223954"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/jpet.120.265595","article-title":"ELX-02 Generates Protein via Premature Stop Codon Read-Through without Inducing Native Stop Codon Read-Through Proteins","volume":"374","author":"Crawford","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/cpdd.647","article-title":"Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ELX-02, a Potential Treatment for Genetic Disorders Caused by Nonsense Mutations, in Healthy Volunteers","volume":"8","author":"Leubitz","year":"2019","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/jcph.1807","article-title":"Phase 1 Renal Impairment Trial Results Supports Targeted Individualized Dosing of ELX-02 in Patients With Nephropathic Cystinosis","volume":"61","author":"Haverty","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/cpdd.914","article-title":"A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX-02 in Healthy Subjects","volume":"10","author":"Leubitz","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1021\/acsmedchemlett.6b00006","article-title":"Design of Novel Aminoglycoside Derivatives with Enhanced Suppression of Diseases-Causing Nonsense Mutations","volume":"7","author":"Sabbavarapu","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e202200497","DOI":"10.1002\/cmdc.202200497","article-title":"Chemo-Enzymatic Synthesis of Pseudo-Trisaccharide Aminoglycoside Antibiotics with Enhanced Nonsense Read-through Inducer Activity","volume":"18","author":"Lee","year":"2022","journal-title":"Chem. Med. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/ja.2017.112","article-title":"Chemotherapeutics Overcoming Nonsense Mutation-Associated Genetic Diseases: Medicinal Chemistry of Negamycin","volume":"71","author":"Taguchi","year":"2018","journal-title":"J. Antibiot."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/jb\/mvg203","article-title":"Negamycin Restores Dystrophin Expression in Skeletal and Cardiac Muscles of Mdx Mice","volume":"134","author":"Arakawa","year":"2003","journal-title":"J. Biochem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1128\/AAC.00455-07","article-title":"Negamycin Binds to the Wall of the Nascent Chain Exit Tunnel of the 50S Ribosomal Subunit","volume":"51","author":"Schroeder","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1002\/cmdc.201402208","article-title":"Discovery of Natural Products Possessing Selective Eukaryotic Readthrough Activity: 3-Epi-Deoxynegamycin and Its Leucine Adduct","volume":"9","author":"Taguchi","year":"2014","journal-title":"Chem. Med. Chem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1021\/acsmedchemlett.9b00273","article-title":"New Negamycin-Based Potent Readthrough Derivative Effective against TGA-Type Nonsense Mutations","volume":"10","author":"Hamada","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"109059","DOI":"10.1016\/j.neuropharm.2022.109059","article-title":"Influence of Novel Readthrough Agents on Myelin Protein Zero Translation in the Peripheral Nervous System","volume":"211","author":"Otani","year":"2022","journal-title":"Neuropharmacology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"4889","DOI":"10.1128\/AAC.48.12.4889-4891.2004","article-title":"Effects of a Number of Classes of 50S Inhibitors on Stop Codon Readthrough during Protein Synthesis","volume":"48","author":"Thompson","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/gut.2008.169805","article-title":"Restoration of APC Gene Function in Colorectal Cancer Cells by Aminoglycoside- and Macrolide-Induced Read-through of Premature Termination Codons","volume":"59","author":"Zilberberg","year":"2010","journal-title":"Gut"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00109-015-1364-1","article-title":"A Flow Cytometry-Based Reporter Assay Identifies Macrolide Antibiotics as Nonsense Mutation Read-through Agents","volume":"94","author":"Caspi","year":"2016","journal-title":"J. Mol. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3233\/JND-170230","article-title":"Analysis of Azithromycin Monohydrate as a Single or a Combinatorial Therapy in a Mouse Model of Severe Spinal Muscular Atrophy","volume":"4","author":"Osman","year":"2017","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Dabrowski, M., Bukowy-Bieryllo, Z., Jackson, C.L., and Zietkiewicz, E. (2021). Properties of Non-Aminoglycoside Compounds Used to Stimulate Translational Readthrough of PTC Mutations in Primary Ciliary Dyskinesia. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094923"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Campofelice, A., Lentini, L., Di Leonardo, A., Melfi, R., Tutone, M., Pace, A., and Pibiri, I. (2019). Strategies against Nonsense: Oxadiazoles as Translational Readthrough-Inducing Drugs (TRIDs). Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20133329"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature05756","article-title":"PTC124 Targets Genetic Disorders Caused by Nonsense Mutations","volume":"447","author":"Welch","year":"2007","journal-title":"Nature"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.4049\/jimmunol.1801045","article-title":"Circulating Truncated Alpha-1 Antitrypsin Glycoprotein in Patient Plasma Retains Anti-Inflammatory Capacity","volume":"202","author":"Reeves","year":"2019","journal-title":"J. Immunol."},{"key":"ref_87","first-page":"103515","article-title":"Translational Readthrough of Ciliopathy Genes BBS2 and ALMS1 Restores Protein, Ciliogenesis and Function in Patient Fibroblasts","volume":"70","author":"Eintracht","year":"2021","journal-title":"E Bio. Med."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Bezzerri, V., Lentini, L., Api, M., Busilacchi, E.M., Cavalieri, V., Pomilio, A., Diomede, F., Pegoraro, A., Cesaro, S., and Poloni, A. (2022). Novel Translational Read-through-Inducing Drugs as a Therapeutic Option for Shwachman-Diamond Syndrome. Biomedicines, 10.","DOI":"10.3390\/biomedicines10040886"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejmech.2018.09.057","article-title":"Rescuing the CFTR Protein Function: Introducing 1,3,4-Oxadiazoles as Translational Readthrough Inducing Drugs","volume":"159","author":"Pibiri","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ejmech.2016.06.048","article-title":"Exploring the Readthrough of Nonsense Mutations by Non-Acidic Ataluren Analogues Selected by Ligand-Based Virtual Screening","volume":"122","author":"Pibiri","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1093\/hmg\/ddw184","article-title":"Functional Rescue of REP1 Following Treatment with PTC124 and Novel Derivative PTC-414 in Human Choroideremia Fibroblasts and the Nonsense-Mediated Zebrafish Model","volume":"25","author":"Moosajee","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ejmech.2015.06.038","article-title":"Enhancement of Premature Stop Codon Readthrough in the CFTR Gene by Ataluren (PTC124) Derivatives","volume":"101","author":"Pibiri","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1164\/rccm.201601-0154OC","article-title":"Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations","volume":"194","author":"Mutyam","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Benhabiles, H., Gonzalez-Hilarion, S., Amand, S., Bailly, C., Pr\u00e9votat, A., Reix, P., Hubert, D., Adriaenssens, E., Rebuffat, S., and Tulasne, D. (2017). Optimized Approach for the Identification of Highly Efficient Correctors of Nonsense Mutations in Human Diseases. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0187930"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1038\/s41467-021-24575-x","article-title":"A Small Molecule That Induces Translational Readthrough of CFTR Nonsense Mutations by ERF1 Depletion","volume":"12","author":"Sharma","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e2122004119","DOI":"10.1073\/pnas.2122004119","article-title":"2-Guanidino-Quinazoline Promotes the Readthrough of Nonsense Mutations Underlying Human Genetic Diseases","volume":"119","author":"Bidou","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1084\/jem.20081940","article-title":"Nonaminoglycoside Compounds Induce Readthrough of Nonsense Mutations","volume":"206","author":"Du","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"12508","DOI":"10.1073\/pnas.1605336113","article-title":"Ataluren Stimulates Ribosomal Selection of Near-Cognate TRNAs to Promote Nonsense Suppression","volume":"113","author":"Roy","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e2020599118","DOI":"10.1073\/pnas.2020599118","article-title":"Ataluren and Aminoglycosides Stimulate Read-through of Nonsense Codons by Orthogonal Mechanisms","volume":"118","author":"Ng","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1038\/s41467-022-30080-6","article-title":"Ataluren Binds to Multiple Protein Synthesis Apparatus Sites and Competitively Inhibits Release Factor-Dependent Termination","volume":"13","author":"Huang","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1021\/acsmedchemlett.8b00558","article-title":"Deciphering the Nonsense Readthrough Mechanism of Action of Ataluren: An in Silico Compared Study","volume":"10","author":"Tutone","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Michorowska, S. (2021). Ataluren\u2014Promising Therapeutic Premature Termination Codon Readthrough Frontrunner. Pharmaceuticals, 14.","DOI":"10.3390\/ph14080785"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1016\/j.stemcr.2022.08.005","article-title":"Investigation of PTC124-Mediated Translational Readthrough in a Retinal Organoid Model of AIPL1-Associated Leber Congenital Amaurosis","volume":"17","author":"Leung","year":"2022","journal-title":"Stem Cell Rep."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Beryozkin, A., Samanta, A., Gopalakrishnan, P., Khateb, S., Banin, E., Sharon, D., and Nagel-Wolfrum, K. (2022). Translational Read-Through Drugs (TRIDs) Are Able to Restore Protein Expression and Ciliogenesis in Fibroblasts of Patients with Retinitis Pigmentosa Caused by a Premature Termination Codon in FAM161A. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073541"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"V\u00f6ssing, C., Owczarek-Lipska, M., Nagel-Wolfrum, K., Reiff, C., J\u00fcschke, C., and Neidhardt, J. (2020). Translational Read-Through Therapy of RPGR Nonsense Mutations. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228418"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Samanta, A., Stingl, K., Kohl, S., Ries, J., Linnert, J., and Nagel-Wolfrum, K. (2019). Ataluren for the Treatment of Usher Syndrome 2A Caused by Nonsense Mutations. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20246274"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"8234","DOI":"10.1038\/s41598-018-26481-7","article-title":"The Effect of PTC124 on Choroideremia Fibroblasts and IPSC-Derived RPE Raises Considerations for Therapy","volume":"8","author":"Torriano","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e005677","DOI":"10.1161\/JAHA.117.005677","article-title":"Modeling Treatment Response for Lamin A\/C Related Dilated Cardiomyopathy in Human Induced Pluripotent Stem Cells","volume":"6","author":"Lee","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41598-017-00142-7","article-title":"Rescue of the MERTK Phagocytic Defect in a Human IPSC Disease Model Using Translational Read-through Inducing Drugs","volume":"7","author":"Ramsden","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jcf.2015.07.007","article-title":"Limited Premature Termination Codon Suppression by Read-through Agents in Cystic Fibrosis Intestinal Organoids","volume":"15","author":"Vijftigschild","year":"2016","journal-title":"J. Cyst. Fibros."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e004227","DOI":"10.1161\/CIRCEP.116.004227","article-title":"Readthrough-Promoting Drugs Gentamicin and PTC124 Fail to Rescue Nav1.5 Function of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes Carrying Nonsense Mutations in the Sodium Channel Gene SCN5A","volume":"9","author":"Kosmidis","year":"2016","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/hmg\/ddu509","article-title":"Translational Read-through of the RP2 Arg120stop Mutation in Patient IPSC-Derived Retinal Pigment Epithelium Cells","volume":"24","author":"Schwarz","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1093\/hmg\/ddt596","article-title":"Human IPSC Models of Neuronal Ceroid Lipofuscinosis Capture Distinct Effects of TPP1 and CLN3 Mutations on the Endocytic Pathway","volume":"23","author":"Lojewski","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jcf.2020.01.007","article-title":"Efficacy and Safety of Ataluren in Patients with Nonsense-Mutation Cystic Fibrosis Not Receiving Chronic Inhaled Aminoglycosides: The International, Randomized, Double-Blind, Placebo-Controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF)","volume":"19","author":"Konstan","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in Patients with Nonsense Mutation Duchenne Muscular Dystrophy (ACT DMD): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"390","author":"McDonald","year":"2017","journal-title":"Lancet"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s40265-014-0287-4","article-title":"Ataluren: First Global Approval","volume":"74","author":"Ryan","year":"2014","journal-title":"Drugs"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2217\/cer-2021-0196","article-title":"Ataluren Delays Loss of Ambulation and Respiratory Decline in Nonsense Mutation Duchenne Muscular Dystrophy Patients","volume":"11","author":"McDonald","year":"2022","journal-title":"J. Comp. Eff. Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2217\/cer-2019-0086","article-title":"Ataluren Use in Patients with Nonsense Mutation Duchenne Muscular Dystrophy: Patient Demographics and Characteristics from the STRIDE Registry","volume":"8","author":"Muntoni","year":"2019","journal-title":"J. Comp. Eff. Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2217\/cer-2019-0171","article-title":"Safety and Effectiveness of Ataluren: Comparison of Results from the STRIDE Registry and CINRG DMD Natural History Study","volume":"9","author":"Mercuri","year":"2020","journal-title":"J. Comp. Eff. Res."},{"key":"ref_120","unstructured":"(2023, March 12). STRIDE Data Show Translarna\u2122 Delays Loss of Ambulation by More Than Five Years in Boys with Nonsense Mutation Duchenne Muscular Dystrophy. PTC Therapeutics, Inc. Available online: https:\/\/ir.ptcbio.com\/news-releases\/news-release-details\/stride-data-show-translarnatm-delays-loss-ambulation-more-five."},{"key":"ref_121","unstructured":"(2023, March 12). PTC Therapeutics Announces CHMP Recommendation of Translarna\u2122 (Ataluren) Label Update for Non-Ambulatory Patients with Duchenne Muscular Dystrophy. PTC Therapeutics, Inc. Available online: https:\/\/ir.ptcbio.com\/news-releases\/news-release-details\/ptc-therapeutics-announces-chmp-recommendation-translarnatm."},{"key":"ref_122","first-page":"184","article-title":"Early Treatment with Ataluren of a 2-Year-Old Boy with Nonsense Mutation Duchenne Dystrophy","volume":"40","author":"Bitetti","year":"2021","journal-title":"Acta Myol."},{"key":"ref_123","first-page":"121","article-title":"Good Response to the Late Treatment with Ataluren in a Boy with Duchenne Muscular Dystrophy: Could the Previous Mild Course of the Disease Have Affected the Outcome?","volume":"41","author":"Pasca","year":"2022","journal-title":"Acta Myol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/acn3.51306","article-title":"Ataluren for Drug-resistant Epilepsy in Nonsense Variant-mediated Dravet Syndrome and CDKL5 Deficiency Disorder","volume":"8","author":"Devinsky","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1080\/15476286.2019.1632633","article-title":"Aminoglycoside Drugs Induce Efficient Read-through of CDKL5 Nonsense Mutations, Slightly Restoring Its Kinase Activity","volume":"16","author":"Fazzari","year":"2019","journal-title":"RNA Biol."},{"key":"ref_126","unstructured":"(2023, March 12). PTC Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides a Corporate Update. PTC Therapeutics, Inc. Available online: https:\/\/ir.ptcbio.com\/news-releases\/news-release-details\/ptc-therapeutics-reports-fourth-quarter-and-full-year-2019."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1073\/pnas.0813345106","article-title":"Mechanism of PTC124 Activity in Cell-Based Luciferase Assays of Nonsense Codon Suppression","volume":"106","author":"Auld","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1073\/pnas.0909141107","article-title":"Molecular Basis for the High-Affinity Binding and Stabilization of Firefly Luciferase by PTC124","volume":"107","author":"Auld","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"McElroy, S.P., Nomura, T., Torrie, L.S., Warbrick, E., Gartner, U., Wood, G., and McLean, W.H.I. (2013). A Lack of Premature Termination Codon Read-through Efficacy of PTC124 (Ataluren) in a Diverse Array of Reporter Assays. PLoS Biol., 11.","DOI":"10.1371\/journal.pbio.1001593"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/hmg\/ddz280","article-title":"Frontotemporal Dementia Non-Sense Mutation of Progranulin Rescued by Aminoglycosides","volume":"29","author":"Kuang","year":"2020","journal-title":"Hum. Mol. Genet."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1042\/BJ20111912","article-title":"Readthrough of Long-QT Syndrome Type 1 Nonsense Mutations Rescues Function but Alters the Biophysical Properties of the Channel","volume":"443","author":"Harmer","year":"2012","journal-title":"Biochem. J."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/s41598-017-01093-9","article-title":"Aminoglycosides, but Not PTC124 (Ataluren), Rescue Nonsense Mutations in the Leptin Receptor and in Luciferase Reporter Genes","volume":"7","author":"Bolze","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.2147\/DDDT.S207720","article-title":"Escin: A Review of Its Anti-Edematous, Anti-Inflammatory, and Venotonic Properties","volume":"13","author":"Gallelli","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_134","first-page":"759","article-title":"Amlexanox: A Novel Therapeutic for Atopic, Metabolic, and Inflammatory Disease","volume":"93","author":"Dosanjh","year":"2020","journal-title":"Yale J. Biol. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"114895","DOI":"10.1016\/j.bcp.2021.114895","article-title":"The Potential Value of Amlexanox in the Treatment of Cancer: Molecular Targets and Therapeutic Perspectives","volume":"197","author":"Bailly","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1750-1172-7-58","article-title":"Rescue of Nonsense Mutations by Amlexanox in Human Cells","volume":"7","author":"Beghyn","year":"2012","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/pcmedi\/pbaa009","article-title":"RNA-Based Therapies in Animal Models of Leber Congenital Amaurosis Causing Blindness","volume":"3","author":"Wang","year":"2020","journal-title":"Precis. Clin. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.jid.2017.05.011","article-title":"Amlexanox Enhances Premature Termination Codon Read-through in COL7A1 and Expression of Full Length Type VII Collagen: Potential Therapy for Recessive Dystrophic Epidermolysis Bullosa","volume":"137","author":"Atanasova","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.bbadis.2017.12.014","article-title":"Amlexanox Provides a Potential Therapy for Nonsense Mutations in the Lysosomal Storage Disorder Aspartylglucosaminuria","volume":"1864","author":"Banning","year":"2018","journal-title":"Biochim. Et Biophys. Acta (BBA)-Mol. Basis Dis."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/nat.2019.0779","article-title":"Targeting Translation Termination Machinery with Antisense Oligonucleotides for Diseases Caused by Nonsense Mutations","volume":"29","author":"Huang","year":"2019","journal-title":"Nucleic Acid Ther."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e154571","DOI":"10.1172\/JCI154571","article-title":"Small-Molecule ERF3a Degraders Rescue CFTR Nonsense Mutations by Promoting Premature Termination Codon Readthrough","volume":"132","author":"Lee","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1093\/nar\/gkab194","article-title":"Effect of Small Molecule ERF3 Degraders on Premature Termination Codon Readthrough","volume":"49","author":"Balgi","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"100994","DOI":"10.1016\/j.blre.2022.100994","article-title":"Targeting Cereblon in Hematologic Malignancies","volume":"57","author":"Fuchs","year":"2022","journal-title":"Blood Rev."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1021\/acs.jmedchem.0c01489","article-title":"CC-90009: A Cereblon E3 Ligase Modulating Drug That Promotes Selective Degradation of GSPT1 for the Treatment of Acute Myeloid Leukemia","volume":"64","author":"Hansen","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1182\/blood.2020008676","article-title":"CC-90009, a Novel Cereblon E3 Ligase Modulator, Targets Acute Myeloid Leukemia Blasts and Leukemia Stem Cells","volume":"137","author":"Surka","year":"2021","journal-title":"Blood"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1261\/rna.060236.116","article-title":"The Nucleoside Analog Clitocine Is a Potent and Efficacious Readthrough Agent","volume":"23","author":"Friesen","year":"2017","journal-title":"RNA"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.canlet.2014.09.024","article-title":"Clitocine Induces Apoptosis and Enhances the Lethality of ABT-737 in Human Colon Cancer Cells by Disrupting the Interaction of Mcl-1 and Bak","volume":"355","author":"Sun","year":"2014","journal-title":"Cancer Lett."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s10495-016-1273-y","article-title":"Clitocine Potentiates TRAIL-Mediated Apoptosis in Human Colon Cancer Cells by Promoting Mcl-1 Degradation","volume":"21","author":"Sun","year":"2016","journal-title":"Apoptosis"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"D118","DOI":"10.1093\/nar\/gks969","article-title":"HEXEvent: A Database of Human EXon Splicing Events","volume":"41","author":"Busch","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/s41467-020-15140-z","article-title":"2,6-Diaminopurine as a Highly Potent Corrector of UGA Nonsense Mutations","volume":"11","author":"Trzaska","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/humu.22897","article-title":"Defects in TRNA Anticodon Loop 2\u2032-O-Methylation Are Implicated in Nonsyndromic X-Linked Intellectual Disability Due to Mutations in FTSJ1","volume":"36","author":"Guy","year":"2015","journal-title":"Hum. Mutat."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.ymthe.2023.01.014","article-title":"Use of 2,6-Diaminopurine as a Potent Suppressor of UGA Premature Stop Codons in Cystic Fibrosis","volume":"31","author":"Leroy","year":"2023","journal-title":"Mol. Ther."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.biochi.2016.11.008","article-title":"2-Guanidino-Quinazolines as a Novel Class of Translation Inhibitors","volume":"133","author":"Osterman","year":"2017","journal-title":"Biochimie"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"128989","DOI":"10.1016\/j.bmcl.2022.128989","article-title":"Guanidino Quinazolines and Pyrimidines Promote Readthrough of Premature Termination Codons in Cells with Native Nonsense Mutations","volume":"76","author":"Morrill","year":"2022","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/s41419-022-05431-2","article-title":"Translational Readthrough of Nonsense Mutant TP53 by MRNA Incorporation of 5-Fluorouridine","volume":"13","author":"Heldin","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1023\/A:1006416410198","article-title":"5-Fluorouracil: Forty-plus and Still Ticking. A Review of Its Preclinical and Clinical Development","volume":"18","author":"Grem","year":"2000","journal-title":"Investig. New Drugs"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1158\/1078-0432.CCR-06-2890","article-title":"Regulation of P53 Expression in Response to 5-Fluorouracil in Human Cancer RKO Cells","volume":"13","author":"Ju","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1093\/hmg\/dds223","article-title":"Read-through Compound 13 Restores Dystrophin Expression and Improves Muscle Function in the Mdx Mouse Model for Duchenne Muscular Dystrophy","volume":"21","author":"Kayali","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1749-6632.2012.06467.x","article-title":"SMRT Compounds Correct Nonsense Mutations in Primary Immunodeficiency and Other Genetic Models","volume":"1250","author":"Gatti","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Grau, M., Garrido, E., Cozar, M., Rodriguez-Sureda, V., Dom\u00ednguez, C., Arenas, C., Gatti, R.A., Cormand, B., Grinberg, D., and Vilageliu, L. (2015). Evaluation of Aminoglycoside and Non-Aminoglycoside Compounds for Stop-Codon Readthrough Therapy in Four Lysosomal Storage Diseases. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0135873"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3324\/haematol.2018.212118","article-title":"Variable Readthrough Responsiveness of Nonsense Mutations in Hemophilia A","volume":"105","author":"Martorell","year":"2020","journal-title":"Haematologica"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"dmm043281","DOI":"10.1242\/dmm.043281","article-title":"Absence of p.R50X Pygm Read-through in McArdle Disease Cellular Models","volume":"13","author":"Puigros","year":"2020","journal-title":"Dis. Model. Mech."},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Ortu\u00f1o-Costela, M.d.C., Cerrada, V., Moreno-Izquierdo, A., Garc\u00eda-Consuegra, I., Laberthonni\u00e8re, C., Delourme, M., Garesse, R., Arenas, J., Fuster Garc\u00eda, C., and Garc\u00eda Garc\u00eda, G. (2022). Generation of the First Human In Vitro Model for McArdle Disease Based on IPSC Technology. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232213964"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.1016\/j.bmcl.2011.07.107","article-title":"Synthesis and Evaluation of Compounds That Induce Readthrough of Premature Termination Codons","volume":"21","author":"Jung","year":"2011","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1038\/mt.2013.150","article-title":"A New Series of Small Molecular Weight Compounds Induce Read through of All Three Types of Nonsense Mutations in the ATM Gene","volume":"21","author":"Du","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/mt.2013.177","article-title":"Generating SM(a)RTer Compounds for Translation Termination Suppression in A-T and Other Genetic Disorders","volume":"21","author":"Lavin","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1021\/acsmedchemlett.9b00609","article-title":"Pharmacophore-Based Design of New Chemical Scaffolds as Translational Readthrough-Inducing Drugs (TRIDs)","volume":"11","author":"Tutone","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1073\/pnas.1424127112","article-title":"Nonsense Suppression by Near-Cognate TRNAs Employs Alternative Base Pairing at Codon Positions 1 and 3","volume":"112","author":"Roy","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/13\/6\/988\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:54:40Z","timestamp":1760126080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/13\/6\/988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,14]]},"references-count":168,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["biom13060988"],"URL":"https:\/\/doi.org\/10.3390\/biom13060988","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,14]]}}}